Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100
15 oct. 2024 07h00 HE
|
Er-Kim
Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100
SoCalBio’s 26th Annual Two-Day Investor Partnership Conference hosted at the Hyatt Regency Newport Beach for the Medical Device and Biotechnology Industry
18 sept. 2024 13h14 HE
|
Southern California Biomedical Council
The Southern California Biomedical Council announced the full lineup of speakers and presenting companies for its 26th Annual SoCalBio Investor Conference.
BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
31 mai 2024 20h59 HE
|
Robbins LLP
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
10 mai 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
19 mars 2024 06h30 HE
|
Centogene NV
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 ...
CENTOGENE Explores Strategic Alternatives
28 févr. 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Receives French Research Tax Credit Accreditation
24 janv. 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
13 déc. 2023 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
11 avr. 2023 06h30 HE
|
Centogene NV
The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis...
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma
09 mars 2023 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...